Opportunities and challenges in the development of targeted therapies
- 1 February 2004
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 21-27
- https://doi.org/10.1053/j.seminoncol.2004.01.003
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Challenges and opportunities for erlotinib (Tarceva): What does the future hold?Seminars in Oncology, 2003
- Cardiac Dysfunction in the Trastuzumab Clinical Trials ExperienceJournal of Clinical Oncology, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- The basic biology of HER2Annals of Oncology, 2001
- Tamoxifen for early breast cancerPublished by Wiley ,2001
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancersOncogene, 1999
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Ovarian ablation for early breast cancerPublished by Wiley ,1998